ICH Q9(R1) Quality Risk Management Revision – Public Consultation

被引：0
|
作者：
Pluta, Paul L.
机构：
来源：
Journal of Validation Technology | 2021年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 39 条
  • [31] ASSESSING THE RISK OF BIAS IN CLINICAL TRIALS FOR HEALTH TECHNOLOGY ASSESSMENTS: SHOULD EXISTING TOOLS REFLECT THE ICH E9(R1) ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSES?
    Poythress, J.
    Morga, A.
    VALUE IN HEALTH, 2023, 26 (12) : S329 - S329
  • [32] DEVELOPMENT OF ICH Q2 (R1) COMPLIANT IMMUNOPOTENCY ASSAY MEASURING MESENCHYMAL STROMAL CELLS MEDIATED T-CELL INHIBITION
    Govindasamy, V.
    Rajendran, A.
    Lee, Z.
    Lim, C.
    Ganeson-Koo, M.
    Then, K.
    Then, K.
    Ooi, G.
    Cheong, S.
    CYTOTHERAPY, 2023, 25 (06) : S83 - S84
  • [33] Toolkit for ICH E6 (R2) Quality Risk Management for Small to Medium Size Companies
    Andrew Della-Coletta
    Terry Katz
    Kathy Kupka
    Sandy Mohan
    Kamila A. Novak
    Maryrose Petrizzo
    Sarah Ann Silvers
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 900 - 921
  • [34] Toolkit for ICH E6 (R2) Quality Risk Management for Small to Medium Size Companies
    Della-Coletta, Andrew
    Katz, Terry
    Kupka, Kathy
    Mohan, Sandy
    Novak, Kamila A.
    Petrizzo, Maryrose
    Silvers, Sarah Ann
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (04) : 900 - 921
  • [35] Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework
    Mitroiu, Marian
    Teerenstra, Steven
    Rengerink, Katrien Oude
    Petavy, Frank
    Roes, Kit C. B.
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 1037 - 1057
  • [36] Method development and ICH (Q2) R1 validation for the absolute quantification of Der f 1 and Der p 1 allergens in a mite extract depot formulation using a triple quadrupole MS system
    Martino, I
    Bell, A. J.
    Heath, M. D.
    Hewings, S. J.
    Skinner, M. A.
    ALLERGY, 2018, 73 : 214 - 214
  • [37] A Weight-of-Evidence Approach for Assessing Human Carcinogenic Risk of Small Molecule Pharmaceuticals that Reduces Reliance on Conventional Rodent Carcinogenicity Studies: An Overview of the ICH S1B(R1) Addendum
    Escobar, Patricia A.
    Sistare, Frank D.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2022, 63 : 45 - 45
  • [38] Matrix Metalloproteinase-9 and Paraoxonase 1 Q/R192 Gene Polymorphisms and the Risk of Coronary Artery Stenosis in Iranian Subjects
    Fallah, Soudabeh
    Seifi, Morteza
    Ghasemi, Asghar
    Firoozrai, Mohsen
    Samadikuchaksaraei, Ali
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2010, 24 (05) : 305 - 310
  • [39] The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium
    Moghadasi, Setareh
    Meeks, Huong D.
    Vreeswijk, Maaike P. G.
    Janssen, Linda A. M.
    Borg, Ake
    Ehrencrona, Hans
    Paulsson-Karlsson, Ylva
    Wappenschmidt, Barbara
    Engel, Christoph
    Gehrig, Andrea
    Arnold, Norbert
    Hansen, Thomas Van Overeem
    Thomassen, Mads
    Jensen, Uffe Birk
    Kruse, Torben A.
    Ejlertsen, Bent
    Gerdes, Anne-Marie
    Pedersen, Inge Sokilde
    Caputo, Sandrine M.
    Couch, Fergus
    Hallberg, Emily J.
    van den Ouweland, Ans M. W.
    Collee, Margriet J.
    Teugels, Erik
    Adank, Muriel A.
    van der Luijt, Rob B.
    Mensenkamp, Arjen R.
    Oosterwijk, Jan C.
    Blok, Marinus J.
    Janin, Nicolas
    Claes, Kathleen B. M.
    Tucker, Kathy
    Viassolo, Valeria
    Toland, Amanda Ewart
    Eccles, Diana E.
    Devilee, Peter
    Van Asperen, Christie J.
    Spurdle, Amanda B.
    Goldgar, David E.
    Garcia, Encarna Gomez
    JOURNAL OF MEDICAL GENETICS, 2018, 55 (01) : 15 - 20
1234